Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome
暂无分享,去创建一个
R. Califf | G. Brabant | P. Armstrong | M. Simoons | L. Wallentin | H. Drexler | B. Lindahl | S. James | K. Wollert | N. Johnston | T. Kempf | Sylvia Olofsson | T. Peter | Rüdiger Horn-Wichmann | Timo Peter
[1] G. Brabant,et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. , 2007, Clinical chemistry.
[2] H. Drexler,et al. The Transforming Growth Factor-&bgr; Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury , 2006 .
[3] A. Siegbahn,et al. FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease , 2005, Heart.
[4] Robert M Califf,et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.
[5] L. Wallentin,et al. Natriuretic peptides in unstable coronary artery disease. , 2004, European heart journal.
[6] A. Larsson,et al. Biochemical indicators of cardiac and renal function in a healthy elderly population. , 2004, Clinical biochemistry.
[7] M. Lalu,et al. Peroxynitrite in Myocardial Ischemia-Reperfusion Injury , 2004, Heart Failure Reviews.
[8] R. Califf,et al. N‐Terminal Pro‐Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV Substudy , 2003, Circulation.
[9] E. Topol,et al. Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina: One-Year Survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV—Acute Coronary Syndrome) Trial , 2003, Circulation.
[10] M. Sabatine,et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.
[11] C. Vassanelli,et al. [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[12] M. Simoons. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial , 2001, The Lancet.
[13] A. Siegbahn,et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.
[14] Ric,et al. CARDIAC TROPONIN T LEVELS FOR RISK STRATIFICATION IN ACUTE MYOCARDIAL ISCHEMIA , 2000 .
[15] W. D. Fairlie,et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[16] S. Thompson,et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.
[17] F. Harrell,et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. , 1996, The New England journal of medicine.